Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the r...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2022-09-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://kjim.org/upload/pdf/kjim-2022-152.pdf |
| _version_ | 1811260363304337408 |
|---|---|
| author | Soo-Young Na You Sun Kim |
| author_facet | Soo-Young Na You Sun Kim |
| author_sort | Soo-Young Na |
| collection | DOAJ |
| description | The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the rates of complications and surgery. Although anti-TNF agents have changed the course of IBD, there are unmet needs in terms of primary and secondary non-responses and side effects such as infections and malignancies. Novel biologics and small-molecule drugs have been developed for IBD, and the medical treatment options have improved. These drugs include sphingosine-1-phosphate receptor modulators and anti-integrins to block immune cell migration, and cytokine and Janus kinase inhibitors to block immune cell communications. In this review, we discuss the approved novel biologics and small-molecule drugs, including several of those in the late stages of development, for the treatment of IBD. |
| first_indexed | 2024-04-12T18:46:18Z |
| format | Article |
| id | doaj.art-7a060b05f4434130990895b12422f17d |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-12T18:46:18Z |
| publishDate | 2022-09-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-7a060b05f4434130990895b12422f17d2022-12-22T03:20:36ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482022-09-0137590691910.3904/kjim.2022.152170715Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugsSoo-Young Na0You Sun Kim1 Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, KoreaThe incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the rates of complications and surgery. Although anti-TNF agents have changed the course of IBD, there are unmet needs in terms of primary and secondary non-responses and side effects such as infections and malignancies. Novel biologics and small-molecule drugs have been developed for IBD, and the medical treatment options have improved. These drugs include sphingosine-1-phosphate receptor modulators and anti-integrins to block immune cell migration, and cytokine and Janus kinase inhibitors to block immune cell communications. In this review, we discuss the approved novel biologics and small-molecule drugs, including several of those in the late stages of development, for the treatment of IBD.http://kjim.org/upload/pdf/kjim-2022-152.pdfbiological productssmall molecule drugsinflammatory bowel diseasescrohn diseasecolitisulcerative |
| spellingShingle | Soo-Young Na You Sun Kim Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs The Korean Journal of Internal Medicine biological products small molecule drugs inflammatory bowel diseases crohn disease colitis ulcerative |
| title | Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs |
| title_full | Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs |
| title_fullStr | Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs |
| title_full_unstemmed | Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs |
| title_short | Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs |
| title_sort | management of inflammatory bowel disease beyond tumor necrosis factor inhibitors novel biologics and small molecule drugs |
| topic | biological products small molecule drugs inflammatory bowel diseases crohn disease colitis ulcerative |
| url | http://kjim.org/upload/pdf/kjim-2022-152.pdf |
| work_keys_str_mv | AT sooyoungna managementofinflammatoryboweldiseasebeyondtumornecrosisfactorinhibitorsnovelbiologicsandsmallmoleculedrugs AT yousunkim managementofinflammatoryboweldiseasebeyondtumornecrosisfactorinhibitorsnovelbiologicsandsmallmoleculedrugs |